As­traZeneca’s PARP drug Lyn­parza eas­i­ly outscores chemo in PhI­II breast can­cer study

As­traZeneca ap­pears ready to start broad­en­ing the mar­ket for its PARP in­hibitor Lyn­parza. AS­CO or­ga­niz­ers picked the phar­ma gi­ant’s Phase III da­ta for HER-2 neg­a­tive metasta­t­ic breast can­cer for the Sun­day spot­light. And it’s not hard to see why.

The drug was linked with tu­mor shrink­age in 60% of the pa­tients with germline BR­CA1 or BR­CA2 mu­ta­tions tak­ing the drug, com­pared to 29% in the chemo group.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER